Drug intelligence / Profile preview

LT-5001

Development stage: Phase 2
Lead developer: LTT Bio-Pharma
Modality: Small Molecules
Administration: Topical

Overview

LT-5001 is a small molecule drug developed primarily by LTT Bio-Pharma and Lumosa Therapeutics for the treatment of pruritus, particularly uremic pruritus in hemodialysis patients. It acts as a partial mu-opioid receptor antagonist and kappa-opioid receptor agonist, modulating opioid receptors on immune cells to inhibit the transmission of itch signals at peripheral sites. The drug has been investigated in clinical trials for nervous system diseases and skin/musculoskeletal diseases, with its main focus on managing pruritus associated with chronic kidney disease[1][2][3][7].

Targets

KOR (Kappa opioid receptor)MOR (Mu opioid receptor)

Beyond the preview

Go deeper on LT-5001.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on LT-5001.

Explore the full profile